Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2020 | TP53-mutant AML linked to poorer outcomes with decitabine plus venetoclax

Kunhwa Kim • 17 Dec 2020
ASH 2020
Acute Myeloid Leukemia Leukemia Antibodies APR-246 Decitabine Magrolimab Venetoclax

Kunhwa Kim, MD, MPH, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, outlines the results of a post-hoc analysis of a Phase II trial (NCT03404193) investigating the outcomes of patients with TP53-mutant acute myeloid leukemia (AML) when treated with venetoclax plus decitabine in the frontline setting. The study found that TP53-mutant AML patients had a complete response (CR) rate of 35% to decitabine plus venetoclax therapy and a median overall survival (OS) of 5.2 months, compared to a CR of 57% and a median OS of 19.4 months in wild-type TP53 patients. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.

More from Kunhwa Kim

1:21
Cytoreductive therapy is safe and feasible for newly-diagnosed AML
Kunhwa Kim • 17 Dec 2020

Related Videos

1:25
The role of the bone marrow microenvironment in hematological malignancies
Manja Wobus • 17 Apr 2024
2:06
Managing relapsed ALL: the role of novel cellular therapies & importance of conditioning regimens
Christina Peters • 15 Apr 2024
1:14
Promising novel agents in AML: menin inhibitors
Mark Levis • 16 Apr 2024
3:02
EUPLAGIA-1: Phase I trial of GLPG5201, a CD19 CAR-T product, in R/R CLL and Richter's transformation
Valentin Ortiz-Maldonado • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals